drugset / Trial / NCT06660732
Rilonacept in Subjects With Cardiac Sarcoidosis
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary objective of this study is to evaluate the effect of rilonacept, added to standard therapy and compared with standard therapy alone, on improvement in myocardial inflammation in subjects with cardiac sarcoidosis after 24 weeks of therapy.
Timeline
- Start
- 2025-03-05
- Primary completion
- 2026-11
- Completion
- 2027-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rilonacept | Protein / enzyme biologic | 160 mg | Subcutaneous |